Group One Trading’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-64,400
| Closed | -$2.59M | – | 7537 |
|
|
2026
Q1 | $2.59M | Sell |
64,400
-29,500
| -31% | -$636K | 0.01% | 1845 |
|
|
2025
Q4 | $2.36M | Sell |
93,900
-12,700
| -12% | -$298K | ﹤0.01% | 2142 |
|
|
2025
Q3 | $2.41M | Buy |
106,600
+52,100
| +96% | +$1.22M | ﹤0.01% | 2123 |
|
|
2025
Q2 | $943K | Sell |
54,500
-33,700
| -38% | -$624K | ﹤0.01% | 2821 |
|
|
2025
Q1 | $1.93M | Sell |
88,200
-70,000
| -44% | -$1.93M | 0.01% | 1839 |
|
|
2024
Q4 | $5.05M | Sell |
158,200
-77,900
| -33% | -$2.34M | 0.01% | 1162 |
|
|
2024
Q3 | $6.81M | Buy |
236,100
+73,000
| +45% | +$2.7M | 0.02% | 826 |
|
|
2024
Q2 | $6.26M | Sell |
163,100
-102,600
| -39% | -$4.65M | 0.02% | 672 |
|
|
2024
Q1 | $15.6M | Sell |
265,700
-5,600
| -2% | -$357K | 0.06% | 257 |
|
|
2023
Q4 | $16.2M | Sell |
271,300
-158,500
| -37% | -$8.04M | 0.04% | 444 |
|
|
2023
Q3 | $16.3M | Buy |
429,800
+306,500
| +249% | +$13.5M | 0.05% | 300 |
|
|
2023
Q2 | $11.2M | Buy |
123,300
+68,600
| +125% | +$5.92M | 0.04% | 452 |
|
|
2023
Q1 | $3.61M | Sell |
54,700
-121,300
| -69% | -$7M | 0.01% | 1054 |
|
|
2022
Q4 | $9.1M | Buy |
176,000
+111,800
| +174% | +$5.93M | 0.02% | 794 |
|
|
2022
Q3 | $4.38M | Sell |
64,200
-32,600
| -34% | -$1.93M | 0.01% | 1267 |
|
|
2022
Q2 | $4.38M | Sell |
96,800
-50,900
| -34% | -$2.32M | 0.01% | 1403 |
|
|
2022
Q1 | $7.5M | Buy |
147,700
+51,200
| +53% | +$2.26M | 0.01% | 1211 |
|
|
2021
Q4 | $4.56M | Sell |
96,500
-130,200
| -57% | -$5.13M | ﹤0.01% | 1783 |
|
|
2021
Q3 | $7.47M | Buy |
226,700
+191,700
| +548% | +$10.8M | 0.01% | 1324 |
|
|
2021
Q2 | $2.21M | Buy |
35,000
+30,300
| +645% | +$1.56M | ﹤0.01% | 2526 |
|
|
2021
Q1 | $202K | Sell |
4,700
-1,300
| -22% | -$61.5K | ﹤0.01% | 5018 |
|
|
2020
Q4 | $343K | Buy |
+6,000
| New | +$254K | ﹤0.01% | 3608 |
|
|
2020
Q3 | – | Sell |
-6,800
| Closed | -$222K | – | 6041 |
|
|
2020
Q2 | $222K | Hold |
6,800
| – | – | ﹤0.01% | 3286 |
|
|
2020
Q1 | $182K | Sell |
6,800
-14,000
| -67% | -$497K | ﹤0.01% | 2830 |
|
|
2019
Q4 | $637K | Buy |
+20,800
| New | +$576K | ﹤0.01% | 2242 |
|
Other funds holding APLS
Group One Trading's APLS Position: Q4 2025 in Review
Group One Trading sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 14,925 shares — an estimated $350K sold.
Group One Trading first reported a position in APLS in Q3 2019 and held it in 16 quarters. The position peaked at $15.2M in Q4 2023. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.
- Group One Trading reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 14,925 Apellis Pharmaceuticals shares in Q4 2025, an estimated $350K.
- Group One Trading first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 16 quarters.
- Group One Trading's Apellis Pharmaceuticals position peaked at $15.2M in Q4 2023.
- 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.